Entrectinib in the neoadjuvant setting of anaplastic thyroid cancer

Detalhes bibliográficos
Autor(a) principal: Damásio, Inês
Data de Publicação: 2023
Outros Autores: Simões-Pereira, Joana, Donato, Sara, Horta, Mariana, Cavaco, Branca Maria, Rito, Miguel, Gomes, Pedro, Leite, Valeriano
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10362/151472
Resumo: person
id RCAP_7d8770444fa2bf322515d33c8dab6f10
oai_identifier_str oai:run.unl.pt:10362/151472
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Entrectinib in the neoadjuvant setting of anaplastic thyroid cancera case reportSDG 3 - Good Health and Well-beingpersonBACKGROUND: Anaplastic thyroid carcinoma (ATC) is one of the most aggressive solid tumors. ATC is frequently diagnosed at advanced stages with unresectable disease and palliative care is often indicated. Recently, several patient-tailored therapies for ATC are emerging due to advances in molecular profiling of these tumors. Entrectinib is a potent oral selective inhibitor of neutrotrophic tropomyosin receptor kinase (NTRK), ROS1, and anaplastic lymphoma kinase fusions. The experience regarding ATC and other thyroid carcinomas, particularly in the neoadjuvant setting, is minimal. CASE REPORT: We present a case of a 51-year-old female patient presenting with a bulky mass of the left thyroid lobe measuring 100 × 108 × 80 mm that was considered surgically unresectable. While waiting for next-generation sequence (NGS) profiling, lenvatinib was initiated. There was an initial clinical and imagiologic response; however, progression occurred after 12 weeks, and at this time NGS identified an ETV6-NTRK3 fusion and entrectinib was started. After 12 weeks, tumor diameters reduced to a minimum of 68×60×49 mm, and the patient underwent total thyroidectomy plus central lymphadenectomy. Histological diagnosis confirmed an ATC (pT4a R2 N1a). Adjuvant radiotherapy (RT) (60 Grays) with weekly paclitaxel (45 mg/m2) was then administered followed by maintenance entrectinib 600 mg daily. Fluorodeoxyglucose positron emission tomography performed 3 months after completion of RT showed only non-specific uptake in the posterior wall of the hypopharynx and larynx, suggestive of inflammation. CONCLUSION: We report the first case of an ATC with a dramatic response to neoadjuvant therapy with entrectinib, which enabled surgical resection of an ab initio unresectable tumor.NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)RUNDamásio, InêsSimões-Pereira, JoanaDonato, SaraHorta, MarianaCavaco, Branca MariaRito, MiguelGomes, PedroLeite, Valeriano2023-03-31T22:19:32Z2023-02-012023-02-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10362/151472eng2235-0640PURE: 54673664https://doi.org/10.1530/ETJ-22-0179info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2024-03-11T05:33:56Zoai:run.unl.pt:10362/151472Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-20T03:54:36.659957Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Entrectinib in the neoadjuvant setting of anaplastic thyroid cancer
a case report
title Entrectinib in the neoadjuvant setting of anaplastic thyroid cancer
spellingShingle Entrectinib in the neoadjuvant setting of anaplastic thyroid cancer
Damásio, Inês
SDG 3 - Good Health and Well-being
title_short Entrectinib in the neoadjuvant setting of anaplastic thyroid cancer
title_full Entrectinib in the neoadjuvant setting of anaplastic thyroid cancer
title_fullStr Entrectinib in the neoadjuvant setting of anaplastic thyroid cancer
title_full_unstemmed Entrectinib in the neoadjuvant setting of anaplastic thyroid cancer
title_sort Entrectinib in the neoadjuvant setting of anaplastic thyroid cancer
author Damásio, Inês
author_facet Damásio, Inês
Simões-Pereira, Joana
Donato, Sara
Horta, Mariana
Cavaco, Branca Maria
Rito, Miguel
Gomes, Pedro
Leite, Valeriano
author_role author
author2 Simões-Pereira, Joana
Donato, Sara
Horta, Mariana
Cavaco, Branca Maria
Rito, Miguel
Gomes, Pedro
Leite, Valeriano
author2_role author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)
RUN
dc.contributor.author.fl_str_mv Damásio, Inês
Simões-Pereira, Joana
Donato, Sara
Horta, Mariana
Cavaco, Branca Maria
Rito, Miguel
Gomes, Pedro
Leite, Valeriano
dc.subject.por.fl_str_mv SDG 3 - Good Health and Well-being
topic SDG 3 - Good Health and Well-being
description person
publishDate 2023
dc.date.none.fl_str_mv 2023-03-31T22:19:32Z
2023-02-01
2023-02-01T00:00:00Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10362/151472
url http://hdl.handle.net/10362/151472
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 2235-0640
PURE: 54673664
https://doi.org/10.1530/ETJ-22-0179
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799138134642917376

Registros relacionados